Skip to main content
Erschienen in: International Journal of Hematology 5/2019

18.03.2019 | Original Article

Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele

verfasst von: Yuji Nishio, Hirotaka Sakai, Yusuke Saiki, Akiko Uchida, Yu Uemura, Manabu Matsunawa, Yasushi Isobe, Masayuki Kato, Naoto Tomita, Ikuo Miura

Erschienen in: International Journal of Hematology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Light-chain plasma cell myeloma (LC-PCM) is a PCM subtype in which only immunoglobulin light-chain is secreted. However, the absence of immunoglobulin heavy-chain (IGH) production in this condition has not been fully elucidated. To address this issue, we retrospectively analyzed patients at our center with LC-PCM and found a group who had only split signals of IGH gene derived from 14q32/IGH translocations by fluorescence in situ hybridization (FISH). Six patients were identified with only split signals of the IGH gene derived from 14q32/IGH translocations. Five of these patients were newly diagnosed, while one had IgG-λ PCM at presentation, which transformed to λ LC-PCM after treatment. The translocation partners were identified in four patients: two cases of (11;14)(q13;q32) and two cases of (4;14)(p16;q32). The development of LC-PCM appears to be explained by the application of allelic exclusion in these patients, such that 14q32/IGH translocation in one allele contributes to the pathogenesis of PCM and the subsequent loss of the other allele is responsible for the loss of IGH production. These findings suggest that a FISH pattern of IGH with “split and loss” may constitute a unique subgroup of LC-PCM.
Literatur
1.
Zurück zum Zitat Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.CrossRefPubMed Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.CrossRefPubMed
3.
Zurück zum Zitat Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–22.CrossRefPubMed Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–22.CrossRefPubMed
4.
Zurück zum Zitat Mckenna RW, Kyle RA, Kuehl WN, Harris NL, Coupland RW, Fend F. Plasma cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, editors. WHO Classification of Tumors, Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2017. pp. 241–58. Mckenna RW, Kyle RA, Kuehl WN, Harris NL, Coupland RW, Fend F. Plasma cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, editors. WHO Classification of Tumors, Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2017. pp. 241–58.
5.
Zurück zum Zitat Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.CrossRefPubMed Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.CrossRefPubMed
6.
Zurück zum Zitat Szczepański T, van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(–) subgroup of multiple myeloma. Blood. 2000;96:1087–93.PubMed Szczepański T, van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(–) subgroup of multiple myeloma. Blood. 2000;96:1087–93.PubMed
7.
Zurück zum Zitat Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 2004;103:3869–75.CrossRefPubMed Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 2004;103:3869–75.CrossRefPubMed
8.
Zurück zum Zitat McGowan-Jordan J, Simons A, Schmid M. International system for human cytogenomic nomenclature 2016. Basel: Kargener; 2016.CrossRef McGowan-Jordan J, Simons A, Schmid M. International system for human cytogenomic nomenclature 2016. Basel: Kargener; 2016.CrossRef
9.
Zurück zum Zitat Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMed Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMed
10.
Zurück zum Zitat Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMed Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMed
11.
Zurück zum Zitat Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305–10.PubMed Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305–10.PubMed
12.
Zurück zum Zitat Burnet FM. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119–21.CrossRefPubMed Burnet FM. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119–21.CrossRefPubMed
13.
Zurück zum Zitat Pernis B, Chiappino G, Kelus AS, Gell PG. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. J Exp Med. 1965;122:853–76.CrossRefPubMedPubMedCentral Pernis B, Chiappino G, Kelus AS, Gell PG. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. J Exp Med. 1965;122:853–76.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108:2013–9.CrossRefPubMed Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108:2013–9.CrossRefPubMed
16.
Zurück zum Zitat Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1–CD49e– immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1CD49e immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed
17.
Zurück zum Zitat Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121:3413–9.CrossRefPubMed Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121:3413–9.CrossRefPubMed
18.
Zurück zum Zitat Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123:3414–9.CrossRefPubMed Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123:3414–9.CrossRefPubMed
19.
Zurück zum Zitat Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–4.CrossRefPubMed Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–4.CrossRefPubMed
20.
Zurück zum Zitat Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, et al. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135:477–84.CrossRefPubMed Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, et al. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135:477–84.CrossRefPubMed
21.
Zurück zum Zitat Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278–85.CrossRefPubMed Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278–85.CrossRefPubMed
Metadaten
Titel
Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele
verfasst von
Yuji Nishio
Hirotaka Sakai
Yusuke Saiki
Akiko Uchida
Yu Uemura
Manabu Matsunawa
Yasushi Isobe
Masayuki Kato
Naoto Tomita
Ikuo Miura
Publikationsdatum
18.03.2019
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02629-7

Weitere Artikel der Ausgabe 5/2019

International Journal of Hematology 5/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.